Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors
FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer
Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions
Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL